Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.30 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16061182 | 1.00 | IL4I1 (0.35) | IL4I1SCN9ASCN10AHSD11B1PIK3C3 | |
| SCHEMBL16060642 | 1.00 | IL4I1 (0.35) | IL4I1SCN9ASCN10AHSD11B1PIK3C3 | |
| SCHEMBL16058949 | 0.89 | CHRM2 (0.34) | HSD11B1KDM4EALDH1A1TGM2NPY5R | |
| SCHEMBL16058686 | 0.84 | HSD11B1 (0.35) | HSD11B1KDM4EALDH1A1TGM2NPY5R | |
| SCHEMBL14244119 | 0.78 | — | — | |
| SCHEMBL1583691 | 0.77 | IL4I1 (0.33) | IL4I1SCN9ASCN10A | |
| SCHEMBL16059586 | 0.76 | PIK3C3 (0.34) | PIK3C3 | |
| SCHEMBL17138583 | 0.74 | KDM4E (0.39) | HSD11B1KDM4EALDH1A1TGM2NPY5R | |
| SCHEMBL9202125 | 0.74 | KDM4E (0.39) | HSD11B1KDM4EALDH1A1TGM2NPY5R | |
| SCHEMBL23486597 | 0.74 | CDA (0.41) | KDM4EALDH1A1CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023244817-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-9783527-B2 | Indazole ureas and method of use | ABBVIE INC. (US) | 2017-10-10 | — | — | US | disclosed |
| EP-3194404-A1 | INDAZOLE UREAS AND METHOD OF USE | AbbVie Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044386-A1 | INDAZOLE UREAS AND METHOD OF USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075692-A1 | Indazole Ureas and Method of Use | ABBVIE INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160046619-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2016-02-18 | — | — | US | disclosed |
| US-9133183-B2 | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140315917-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046619-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | CSF1R, KIT, CSF3R | IL4I1 191/4885SCN9A 3300/4885SCN10A 4000/4885 |
| US-20140315917-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | CSF1R, KIT, CSF3R | IL4I1 191/4885SCN9A 3300/4885SCN10A 4000/4885 |
| US-20160075692-A1 | Indazole Ureas and Method of Use | SCN8A, SCN7A, SCN3A | IL4I1 2719/4885SCN9A 12/4885SCN10A 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.